TickerTain
TickerTain
NewsroomShortsPortfolioConvergence
NewsroomShortsPortfolioConvergence
$ANTHROPIC·$MA····$INTC····$BLUE-ORIGIN·$SPCX····$CRWV····$CRM····$MSFT····$NVDA····$ORCL····$CURSOR·$AAPL····$OPENAI·$AMZN····$UBER····$GOOGL····$META····$TSLA····$DATABRICKS·$PERPLEXITY·$LYFT····$NBIS····$TSM····$LITE····$ANDURIL·
$ANTHROPIC·$MA····$INTC····$BLUE-ORIGIN·$SPCX····$CRWV····$CRM····$MSFT····$NVDA····$ORCL····$CURSOR·$AAPL····$OPENAI·$AMZN····$UBER····$GOOGL····$META····$TSLA····$DATABRICKS·$PERPLEXITY·$LYFT····$NBIS····$TSM····$LITE····$ANDURIL·
←

pablo

T3 · host / generalist

Practitioner of the forward-deployed engineer model. Described how his team of 50 deployment engineers (growing to 75-100) acts as problem-solvers for enterprise clients, becoming the best sales channel.

8 calls·8 names·50% bull·last heard 3 months ago·SeedRocket TV+1
track recordleaderboard →
hit rate
100%
avg alpha
+33.0pp
scored
1

top calls

best measured alpha vs SPY, then highest conviction · one per company
1st+33.0pp vs SPY
$BFLYButterfly Networkposition

Handheld ultrasound IPO delivered strong returns despite interpretation bottleneck

Butterfly's phone-connected ultrasound democratizes imaging access for remote areas, and the fund realized a very good return at IPO; however, the remaining challenge is AI-assisted interpretation to replace years of sonographer training.

SeedRocket TV2026-06episode →
2ndhigh conviction
$VIRTA-HEALTHVirta Healthposition

Diabetes reversal platform positioned as pre-GLP-1 employer benefit heading to IPO

Virta's employer-paid program reverses type 2 diabetes without insulin, reducing costly complications; now positioned as a mandatory step before GLP-1 coverage, creating a massive B2B2C moat with unicorn valuation and likely IPO within the year.

SeedRocket TV2026-06episode →
3rdhigh conviction
$HAPPY-ROBOTHappy Robotposition

Happy Robot climbs from logistics calls to enterprise execution

Happy Robot is positioned as an enterprise agent platform that begins with concrete logistics workflows and then compounds context across functions. Its traction with top freight brokers, trucking companies, ocean carriers, and DHL suggests the wedge can expand beyond simple voice support into higher-value operational decisions.

a16z2026-06episode →

most discussed · click a bar to filter

  • $BMBL
  • $COLUMBUS-VENTURE-PARTNERS
  • $HIMS
  • $ADMIT-THERAPEUTICS
  • $BB-SCRIPTS

recurring themes

  • AI Drug Discovery3
  • GLP-1 & Metabolic Drugs1
  • Medical Imaging & Diagnostics1
  • Healthcare Systems & Policy1
  • Gene & Cell Therapy1
8 total
$BMBL
···
Bumble
LOWpablo·SeedRocket TV·3 months ago·INFLUENCERS jugando a INVERSORES, SpaceX a 2 BILLONES y 3 MILLONES EN LLAMAS entre Socios -Tertulia
Pablo cites Bumble valuation collapse from $8B to $250M as dating app fatigue signal
Bumble's 97% valuation decline reflects broader dating app fatigue and declining relationship formation among youth driven by smartphone addiction.
"Bumble estaba en 8 billones de de valoración, ahora está en 250 millones de valoración. O sea, la gente ha dejado de utilizar aplicaciones cada vez más."
44:41
$COLUMBUS-VENTURE-PARTNERS
Columbus Venture Partners
LOWpablo·SeedRocket TV·4 months ago·Health Expert: "AI already knows more than your doctor" - SeedRocket Roundtable
Specialized fund with deep mRNA manufacturing expertise backing Viralgen exit
Columbus understands the mRNA production supply chain and backed Viralgen's €4B exit; their operational knowledge in manufacturing infrastructure makes them a key partner for hard-tech health investing.
"esa es un área, todo el tema, como vamos a decir de de producción que yo soy muy bullish y que tengo que agradecerle a Damiá, que también está con nosotros en Vistarta muchas vece…"
60:10
$HIMS
···
Hims & Hers Health
MEDpablo·SeedRocket TV·4 months ago·Health Expert: "AI already knows more than your doctor" - SeedRocket Roundtable
Integrated telehealth-pharmacy-marketing machine targeting multi-billion valuation
Hims & Hers operates a three-layer flywheel — teleconsultation, owned pharmacy fulfillment, and performance marketing — enabling end-to-end control of high-volume conditions like obesity and hair loss, with a path to several billion dollars in valuation.
"Este tipo de compañías que serían Himpson Herz Estados Unidos bolsa y esto cuando puede valer muchos billions, ¿no? Varios billions. Sí, sí. Eh, en realidad es un entramado de tre…"
45:44
$ADMIT-THERAPEUTICS
Admit Therapeutics
MEDpablo·SeedRocket TV·4 months ago·Health Expert: "AI already knows more than your doctor" - SeedRocket Roundtable· position
Blood test predicts Alzheimer's and progression to dementia via beta-amyloid markers
Admit's blood-based assay detects beta-amyloid presence and predicts Alzheimer's progression to dementia, but commercial viability hinges on actionability — currently limited by lack of disease-modifying treatments and personalized intervention evidence.
"Por ejemplo, esta que te decía antes de admit, eh, te puede ya v creo que mucha gente que no hay nadie si tienes si tienes eh los betamiloides para desarrollar el Alzheimer y no s…"
63:37
$BB-SCRIPTS
BB Scripts
MEDpablo·SeedRocket TV·4 months ago·Health Expert: "AI already knows more than your doctor" - SeedRocket Roundtable· position
Maternity digital health point solution fails to scale for venture returns
After 9 years and several million in revenue, BB Scripts cannot scale beyond a ceiling, illustrating why point solutions in digital health generate insufficient IRR for venture portfolios despite decent business fundamentals.
"Tenemos una compañía que trabaja en el sector de maternidad en Estados Unidos que se llama BB Scripts, invertimos hace 9 años o algo así. Es una compañía que va bien, factura vari…"
43:24
$VIRTA-HEALTH
Virta Health
HIGHpablo·SeedRocket TV·4 months ago·Health Expert: "AI already knows more than your doctor" - SeedRocket Roundtable· position
Diabetes reversal platform positioned as pre-GLP-1 employer benefit heading to IPO
Virta's employer-paid program reverses type 2 diabetes without insulin, reducing costly complications; now positioned as a mandatory step before GLP-1 coverage, creating a massive B2B2C moat with unicorn valuation and likely IPO within the year.
"Y ahora tenemos otra que va a salir a bolsa seguramente. Seguramente. Veremos a ver. eh a finales de este año, Birta Health, okay, eh está hace salud cardiometabólica para emplead…"
44:24
$BFLY
···
Butterfly Network
HIGHpablo·SeedRocket TV·4 months ago·Health Expert: "AI already knows more than your doctor" - SeedRocket Roundtable· position
Handheld ultrasound IPO delivered strong returns despite interpretation bottleneck
Butterfly's phone-connected ultrasound democratizes imaging access for remote areas, and the fund realized a very good return at IPO; however, the remaining challenge is AI-assisted interpretation to replace years of sonographer training.
"Butterfly Network es un ecógrafo. Los ecógrafos si alguien le han hecho una ecografía de rodilla, o lo que sea, es un de lo que sea, pueden ser de 1 cosas embarazadas también, ¿eh…"
43:13
$HAPPY-ROBOT
Happy Robot
HIGHpablo·a16z·4 months ago·Pyramid of Work and The Future of Enterprise Automation | The a16z Show· position
Happy Robot climbs from logistics calls to enterprise execution
Happy Robot is positioned as an enterprise agent platform that begins with concrete logistics workflows and then compounds context across functions. Its traction with top freight brokers, trucking companies, ocean carriers, and DHL suggests the wedge can expand beyond simple voice support into higher-value operational decisions.
"Today we actually serve nine of the top 10 freight brokers in the US... With DHL, we've deployed over 40 agents across 80 countries. Agents that are sharing context across regions…"
5:23
9
GLP-1 & Metabolic Drugstailwind
Employer-paid diabetes reversal programs become mandatory step before GLP-1 coverage
Virta Health's model — reverse type 2 diabetes via lifestyle intervention paid by employers — is being inserted as a required gateway before expensive GLP-1 prescriptions, creating a high-margin B2B2C moat in the multi-billion metabolic market.
9
AI Drug Discoverytailwind
mRNA manufacturing infrastructure is the picks-and-shovels play for 200+ therapeutic pipeline
With 200+ mRNA therapeutics in clinical trials but production methods unchanged since the 1970s — expensive, poor scaling, concentrated supply chain — investing in novel manufacturing platforms captures value across the entire modality.
8
AI Drug Discoverytailwind
FDA accepts AI-powered synthetic control arms to accelerate clinical trials
The FDA now permits using historical patient data with AI to replace placebo arms in pivotal trials, cutting recruitment costs and time; EMA has not yet followed, creating a regulatory arbitrage favoring US development.
8
Medical Imaging & Diagnosticstailwind
Liquid biopsy detects cancer recurrence 16 months earlier but US adoption dwarfs Europe
Circulating tumor DNA assays provide 16-month lead time over imaging for breast cancer recurrence, enabling life decisions like pregnancy before treatment; US reimbursement drives 70% adoption vs <10% in Europe, forcing EU startups to flip to US for commercial viability.
8
Healthcare Systems & Policytailwind
US for-profit system enables price appreciation; EU public systems drive price erosion
US healthcare's employer-insurer-provider incentives allow persistent price increases post-launch, while European single-payer systems systematically push drug/device prices down, making US the primary commercialization market for health tech innovation.
8
Gene & Cell Therapytailwind
Ex vivo organ perfusion enables treatment of organs outside the body before transplant
Bloodless perfusion solutions keep donor organs viable at body temperature, allowing drug treatment of organs ex vivo (e.g., reversing fatty liver) before reimplantation — a platform applicable to transplant and eventually in situ organ therapy.
7
AI Drug Discoverytailwind
US health data access enables faster AI model training vs EU GDPR constraints
US portfolio companies train medical AI models years faster due to broader data interoperability and private-sector incentives, while EU's consensus-based approach delays data access and model iteration cycles.
7
Enterprise AI Adoptionheadwind
Digital health point solutions fail venture return thresholds; platforms win
Single-condition digital tools (e.g., maternity apps) hit revenue ceilings and deliver 3-5x returns over 9+ years — insufficient for VC — while integrated platforms combining telehealth, pharmacy, and marketing (Hims & Hers) build defensible flywheels worth billions.